Pharma BD Deal Intelligence

Genentech, Inc. (Roche Group) / OMass Therapeutics Ltd.

2025 · Licensing/Option · $420M · Complete

OMass Therapeutics entered an exclusive collaboration and license agreement with Genentech, a member of the Roche Group, granting Genentech rights to develop and commercialize OMass' preclinical oral small molecule program for inflammatory bowel disease. OMass receives $20 million upfront plus more than $400 million in potential preclinical, development, commercial and net sales milestones, and is eligible for tiered royalties on net sales. OMass leads initial preclinical development through candidate selection; Genentech is responsible for clinical development, regulatory activities, manufacturing and commercialization.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals